If you are having trouble adhering to a standard 3-drug regimen, talk to your doctor about taking 2 nucleoside reverse transcriptase inhibitors
Soon the benefit of combining therapies began to become clearer (the combination trend had actually begun earlier with nucleoside reverse transcriptase inhibitors
, NRTIs), and the treatment paradigm of 2 NRTIs and a PI became the unique model by which other therapies were measured.
The indication for FUZEON in the European Union is for "use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following antiretroviral classes, protease inhibitors, non-nucleoside reverse transcriptase inhibitors
and nucleoside reverse transcriptase inhibitors
, or who have intolerance to previous antiretroviral regimens.
Nucleoside reverse transcriptase inhibitors
(NRTIs) in particular have been associated with lactic acidosis (elevated levels of lactic acid in the blood) and hepatic steatosis (fatty liver).
Existing categories -- nucleoside reverse transcriptase inhibitors
(NRTIs), non-nucleoside reverse transcriptase inhibitors
(NNRTIs), and protease inhibitors (PIs) -- as well as novel categories such as entry inhibitors, immune-based therapies, zinc finger inhibitors and integrate inhibitors have several drugs in the pipeline that can address the urgent requirement for new antiretroviral drugs," says Frost & Sullivan Research Analyst Raghunath Tantry.
New reports suggest that zidovudine resistance mutations may be important for resistance to other nucleoside reverse transcriptase inhibitors
(NRTIs), and a novel mechanism for resistance has been described.
The regimens that have been best documented to work in this context are built on a backbone of ritonavir (Norvir) and saquinavir (Fortovase) along with nucleoside reverse transcriptase inhibitors
Using the non-completer-failure analysis, the results indicate that through 48 weeks of treatment with SUSTIVA plus two nucleoside reverse transcriptase inhibitors
(NRTIs), 94 percent (65/69) of patients maintained viral load less than 50 copies/ml.